Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 27, 2025 18:14 ET | Source: Monteverde & Associates PC

HAPPY THANKSGIVING AND ALERT: The M&A Class Action Firm Continues to Investigate the Merger – EXAS, SEE, CDTX, and MRSN

NEW YORK, Nov. 27, 2025 (GLOBE NEWSWIRE) -- We wish you a Happy Thanksgiving and Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), who has...
November 13, 2025 17:30 ET | Source: Monteverde & Associates PC

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Mersana Therapeutics, Inc. (NASDAQ: MRSN)

NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for...
June 19, 2023 18:54 ET | Source: Kaplan Fox & Kilsheimer LLP

INVESTOR ALERT: Kaplan Fox Investigates Mersana Therapeutics, Inc. (Nasdaq: MRSN)

NEW YORK, June 19, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating potential claims on behalf of investors who purchased Mersana Therapeutics, Inc....
June 12, 2019 08:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Announces Appointment of Brian C. DeSchuytner as Senior Vice President of Finance and Product Strategy

Brings Significant Strategic and Operational Experience from Leading Oncology Companies Company Announces Chief Financial Officer Transition CAMBRIDGE, Mass., June 12, 2019 (GLOBE...
November 27, 2018 08:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Appoints Dirk Huebner, M.D., as Chief Medical Officer

CAMBRIDGE, Mass., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
November 13, 2018 07:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Announces Third Quarter 2018 Financial Results and Provides Business Updates

XMT-1536 Phase 1 Dose Escalation Ongoing with Data Expected in the First Half of 2019 XMT-1522 Phase 1 Dose Escalation Enrollment Resumed Mersana to Present New Data on Dolasynthen and...
November 12, 2018 09:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Presents Pre-clinical Data at AACR-NCI-EORTC on Two Additional, Proprietary Antibody Drug Conjugate Platforms and a Pre-clinical Update for XMT-1522 in Non-small Cell Lung Cancer

CAMBRIDGE, Mass., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
November 12, 2018 07:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Scientists Present Updates on XMT-1522, XMT-1536 and the Dolaflexin Platform at World ADC 2018

Mersana Chief Scientific Officer, Timothy B. Lowinger, Ph.D. to chair 2018 Conference CAMBRIDGE, Mass., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage...
November 08, 2018 17:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics to Present at the Credit Suisse 27th Annual Healthcare Conference

CAMBRIDGE, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
November 06, 2018 17:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics to Host Conference Call Announcing Third Quarter 2018 Financial Results and Business Updates

CAMBRIDGE, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...